Gene therapy for prostate cancer using the cytosine deaminase/uracil phosphoribosyltransferase suicide system

Journal of Gene Medicine

Volumn 5, Issue 1, 2003, Pages 30-37

  Miyagi, Tohru ^a   Koshida, Kiyoshi ^a   Hori, Osamu ^a   Konaka, Hiroyuki ^a   Katoh, Hiroaki ^a   Kitagawa, Yasuhide ^a   Mizokami, Atsushi ^a   Egawa, Masayuki ^a   Ogawa, Satoshi ^a   Hamada, Hirohumi ^b   Namiki, Mikio ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

5 fluorocytosine; Cancer suicide gene therapy; E. coli cytosine deaminase gene; E. coli uracil phosphoribosyltransferase gene; Prostate cancer; Replication defective adenovirus vector

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; URACIL PHOSPHORIBOSYLTRANSFERASE; ANTINEOPLASTIC ANTIMETABOLITE; DEAMINASE; GLYCOSYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL GENE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACTIVATION; DRUG EFFICACY; DRUG SENSITIVITY; ESCHERICHIA COLI; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IC 50; INOCULATION; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SUICIDE GENE THERAPY; VIRAL GENE DELIVERY SYSTEM; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; GENE THERAPY; GENE VECTOR; GENETICS; PROSTATE TUMOR;

ADENOVIRIDAE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE; CYTOSINE DEAMINASE; FLUOROURACIL; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NUCLEOSIDE DEAMINASES; PENTOSYLTRANSFERASES; PROSTATIC NEOPLASMS;

EID: 0037927844     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.317     Document Type: Article

References (24)

1. Mcmasters RA, Saylors L, Jones KE, et al. Lack of bystander killing in herpes simplex virus thymidine kinase-transduced colon cell lines due to deficient connexin43 gap junction formation. Hum Gene Ther 1998; 9: 2253-2261.
2. Shirakawa T, Gardner TA, Ko S, et al. Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model. J Urol 1999; 162: 949-954.
3. Lawrence TS, Rehemtulla A, Ng NY, et al. Preferential cyotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-fluorocytosine. Cancer Res 1998; 58: 2588-2593.
4. Koyama F, Sawada H, Fujii H, et al. Adenoviral transfer of Escherichia coli uracil phosphoribosyltransferase (UPRT) gene to modulate the sensitivity of the human colon cancer cells to 5-fluorouracil. Eur J Cancer 2000; 36: 2403-2410.
5. Inaba M, Sawada H, Sadata A, et al. Circumvention of 5-fluorouracil resistance in human stomach cancer cells by uracil phosphoribosyltransferase gene transduction. Jpn J Cancer Res 1999; 90: 349-354.
6. Kanai K, Kawakami T, Hamada H, et al. Adenovirus mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res 1998; 58: 1946-1951.
7. Kawamura K, Tasaki K, Hamada H, et al. Expression of Escherichia coli uracil phosphoribosyltransferase gene in murine colon carcinoma cells augments the antitumoral effect of 5-fluorouracil and induces protective immunity. Cancer Gene Ther 2000; 7: 637-643.
8. Tiraby M, Cazaux C, Baron M, et al. Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol Lett 1998; 167: 41-49.
9. Adachi Y, Tamiya T, Ichikawa T, et al. Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine. Hum Gene Ther 2000; 11: 77-89.
10. Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 15: 3813-3822.
11. Koyama F, Sawada H, Hirao T, et al. Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of Esherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine. Cancer Gene Ther 2000; 7: 1015-1022.
12. Chung-Faye CA, Chen MJ, Green NK, et al. In vivo gene therapy for colon cancer using adenovirus-mediated transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther 2001; 8: 1547-1554.
13. Galabrisi P, Chabner BA (eds). Antineoplastic agents. In Goodman and Gilman's Pharmacological Basis for Therapeutics (9th edn). Gilman AG, Rall T, Nies AS, Taylor P (eds). Pergamon Press: New York, 1225-1287.
14. Petit E, Milano G, Levi F, et al. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res 1988; 48: 1676-1679.
15. Etienne MG, Cheradame S, Fischel JL, et al. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13 1663-1670.
16. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6: 1322-1327.
17. Harris BE, Song R, Soong S, et al. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197-201.
18. Lenz HJ, Leichman CG, Danenberg KD, et al. Thymidylate synthetase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996; 14: 176-182.
19. Leichman CG, Lenz HJ, Leichman L, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997; 15: 3223-3229.
20. Copur S, Aiba K, Drake JC, et al. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 1995; 49: 1419-1426.
21. Inaba M, Naoe Y, Mitsuhashi J. Mechanisms for 5-fluorouracil resistance in human colon cancer DLD-1 cells. Biol Pharm Bull 1998; 21: 569-573.
22. Wang FS, Aschele C, Sobrero A, et al. Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance. Cancer Res 1993; 53: 3677-3680.
23. Huber BE, Austin EA, Richards CA, et al. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A 1994; 91: 8302-8306.
24. Mehta PP, Lokeshwar BL, Schiller PC, et al. Gap-junctional communication in normal and neoplastic prostate epithelial cells and its regulation by camp. Mol Carcinogenesis 1996; 15 18-32.